晚期阿尔茨海默病及相关痴呆患者及其照护者的姑息治疗:一项随机临床试验方案
本研究为多中心随机临床试验方案,计划在五家美国医院纳入424对住院晚期阿尔茨海默病及相关痴呆(ADRD)患者与家庭照护者,1:1随机分为ADRD-PC干预组(痴呆特异性姑息治疗、标准化照护者教育、过渡期护理)与对照组(公开痴呆照护教育材料),主要结局为出院后60天医院转诊,次要结局涵盖患者症状治疗与控制、社区姑息治疗或临终关怀使用、新养老院转介及照护者沟通、共同决策与痛苦,采用意向性分析。
要点
- 晚期ADRD患者专科姑息治疗可及性有限,导致沉重治疗与不必要住院。
- 研究纳入424对住院晚期ADRD患者与家庭照护者,1:1随机分组。
- 主要结局为出院后60天医院转诊,次要结局包括症状控制与照护者痛苦。
核心结论
- 研究结果将确定针对晚期ADRD公共卫生影响及症状困扰、沉重治疗和照护者压力的干预措施的有效性。
- 许多照护者在晚期ADRD中优先考虑舒适,但共同决策罕见,住院为痴呆特异性姑息治疗创造机会。
- 研究结果将为推进全面痴呆特异性姑息治疗加过渡期护理的照护重构提供信息。
研究设计与样本
- 多中心随机临床试验,设于五家地理分布不同的美国医院。
- 主要研究者和结局评估者设盲。
- 患者-照护者双人组按1:1随机,计划纳入N=424对住院晚期ADRD患者及其家庭照护者。
- 干预组接受ADRD-PC项目:痴呆特异性姑息治疗、标准化照护者教育、过渡期护理;对照组接受公开的痴呆照护教育材料。
- 结局在出院后30天(中期)和60天测量,分析采用意向性分析。
主要发现
- 主要结局为60天医院转诊,定义为通过病历审查和照护者访谈确定的急诊就诊或住院(目标1)。
- 次要患者中心结局通过30天和60天病历审查及照护者电话访谈确定,包括症状治疗、症状控制、社区姑息治疗或临终关怀使用、新养老院转介(目标2)。
- 次要照护者中心结局包括关于预后和照护目标的沟通、关于住院和其他治疗的共同决策、照护者痛苦(目标3)。
- 预设探索性分析将检验性别作为生物学变量和GDS分期的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited access to specialized palliative care exposes persons with late-stage Alzheimer's disease and related dementias (ADRD) to burdensome treatment and unnecessary hospitalization and their caregivers to avoidable strain and financial burden. Addressing this unmet need, the purpose of this study was to conduct a randomized clinical trial (RCT) of the ADRD-Palliative Care (ADRD-PC) program. METHODS: The study will use a multisite, RCT design and will be set in five geographically diverse US hospitals. Lead investigators and outcome assessors will be masked. The study will use 1:1 randomization of patient-caregiver dyads, and sites will enroll N = 424 dyads of hospitalized patients with late-stage ADRD with their family caregivers. Intervention dyads will receive the ADRD-PC program of (1) dementia-specific palliative care, (2) standardized caregiver education, and (3) transitional care. Control dyads will receive publicly available educational material on dementia caregiving. Outcomes will be measured at 30 days (interim) and 60 days post-discharge. The primary outcome will be 60-day hospital transfers, defined as visits to an emergency department or hospitalization ascertained from health record reviews and caregiver interviews (aim 1). Secondary patient-centered outcomes, ascertained from 30- and 60-day health record reviews and caregiver telephone interviews, will be symptom treatment, symptom control, use of community palliative care or hospice, and new nursing home transitions (aim 2). Secondary caregiver-centered outcomes will be communication about prognosis and goals of care, shared decision-making about hospitalization and other treatments, and caregiver distress (aim 3). Analyses will use intention-to-treat, and pre-specified exploratory analyses will examine the effects of sex as a biologic variable and the GDS stage. DISCUSSION: The study results will determine the efficacy of an intervention that addresses the extraordinary public health impact of late-stage ADRD and suffering due to symptom distress, burdensome treatments, and caregiver strain. While many caregivers prioritize comfort in late-stage ADRD, shared decision-making is rare. Hospitalization creates an opportunity for dementia-specific palliative care, and the study findings will inform care redesign to advance comprehensive dementia-specific palliative care plus transitional care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04948866. Registered on July 2, 2021.
引用
- Toles M, Kistler C, Lin FC, et al. Palliative care for persons with late-stage Alzheimer's and related dementias and their caregivers: protocol for a randomized clinical trial. Trials. 2023. PMID: 37743478. doi:10.1186/s13063-023-07614-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。